Patients taking edoxoban after heart valve surgery had lower risk of stroke, blood clots.

A study presented at the American Heart Association's Scientific Sessions 2024 found that patients who took edoxaban, an oral anticoagulant, after heart valve surgery had a lower risk of stroke and blood clots compared to those taking warfarin. Edoxaban was shown to be as effective as warfarin in reducing these risks, offering a potential alternative treatment option for patients recovering from heart valve surgery. The study highlighted the benefits of edoxaban, which does not require frequent blood tests and has a predictable pharmacokinetic profile, making it easier for patients to manage post-surgery treatment. [Extracted from the article]